Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01154114 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects
A Phase 1 study of Atherosclerosis, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT01154114 is a Phase 1 study of Atherosclerosis that has completed, run by GlaxoSmithKline. The registered enrollment target is 24 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT01154114, a Phase 1 study of Atherosclerosis, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine any differences in pharmacokinetic parameters of darapladib when dosed to people with moderate liver disease as compared to when dosed in normal healthy volunteers.
Conditions Studied
Interventions
- DRUG darapladib
Study Locations (2)
Florida
- GSK Investigational Site - Miami
- GSK Investigational Site - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2010-07-01 |
| Est. Completion | 2010-10-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01154114
The ClinicalTrials.gov registry entry for NCT01154114 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (98% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which darapladib is the first listed.
NCT01154114 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT01154114 about?
NCT01154114 is a clinical study titled "Study to Evaluate Darapladib in Moderately Hepatically Impaired Subjects". The purpose of this study is to determine any differences in pharmacokinetic parameters of darapladib when dosed to people with moderate liver disease as compared to when dosed in normal healthy volunteers.
What is the current status of trial NCT01154114?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2010-07-01. Estimated completion is 2010-10-15.
What conditions does trial NCT01154114 study?
This clinical trial studies the following conditions: Atherosclerosis.
What interventions are being tested in trial NCT01154114?
The interventions under investigation include: darapladib (DRUG).
Who is sponsoring clinical trial NCT01154114?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01154114 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical and Histological Analysis of Mesenchymal Stem Cells in Amputation
COMPLETED · Phase 1
-
Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque
COMPLETED · Phase 1
-
Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus
COMPLETED · Phase 1
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Text Education About Cardiovascular Health and HIV (TEACH-HIV)
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.